Pinealon (EDR): What the Neuroprotective Research Actually Shows

Pinealon is a synthetic tripeptide composed of three amino acids – L-glutamic acid, L-aspartic acid and L-arginine (Glu-Asp-Arg, abbreviated EDR) – with the CAS number 175175-23-2 and a molecular weight of 418.407 Da. It was developed at the Saint Petersburg Institute of Bioregulation and Gerontology under the research programme of Professor Vladimir Khavinson, the same group that produced epitalon.

Despite its name, pinealon was not isolated from pineal gland tissue. The name refers to its proposed target effects on pineal and brain function. The peptide was originally isolated from Cortexin, a polypeptide neuroprotective drug extracted from animal brain cortex. Khavinson’s group then synthesised the EDR tripeptide as a standalone compound and classified it as a “cytogen” – a category within the broader Khavinson bioregulator framework describing tissue-specific short peptides.

The bottom line: Pinealon is a synthetic tripeptide bioregulator from the Khavinson research programme, isolated from brain cortex extract and proposed to act on neuronal tissue through a mechanism distinct from receptor-mediated signalling.

Pinealon’s proposed mechanism is fundamentally different from most peptides. Rather than binding cell-surface or cytoplasmic receptors, pinealon is hypothesised to cross lipid bilayers – including both cell and nuclear membranes – and interact directly with DNA in the nucleus. This was first demonstrated using fluorescence-labelled peptides in HeLa cell studies, which showed nuclear localisation of the EDR peptide.

DNA Binding and Gene Expression

Molecular modelling studies have identified two specific DNA binding motifs for the EDR peptide: d(CCTGCC)₂ and d(CCAGC)₂. These motifs have been located in the promoter regions of genes encoding key neuroprotective and antioxidant proteins:

• SOD2 – mitochondrial superoxide dismutase, a primary antioxidant enzyme
• GPX1 – glutathione peroxidase, another antioxidant defence
• PPARA and PPARG – peroxisome proliferator-activated receptors involved in neuroprotection
• TPH1 – tryptophan hydroxylase 1, the rate-limiting enzyme in serotonin biosynthesis

The EDR peptide also has binding sites in the promoter regions of genes relevant to Alzheimer’s disease pathogenesis, including CASP3 (caspase-3), NES, GAP43 and APOE, as reported in molecular docking studies.

Serotonin Synthesis Pathway

One proposed downstream effect of pinealon’s DNA interaction is upregulation of tryptophan hydroxylase (TPH1), the rate-limiting enzyme in serotonin production. Molecular docking simulations suggest that pinealon has a lower (more stable) binding energy when interacting with DNA compared to other bioregulatory peptides. In cell culture studies, pinealon reportedly increased serotonin synthesis approximately 1.9-fold in younger brain cortex cell cultures compared to controls.

The connection to the pineal gland comes through TPH1’s expression pattern: TPH1 is expressed in the pineal gland (where it supports melatonin production via serotonin) as well as in peripheral tissues. This provides a molecular link between pinealon’s proposed gene-expression effects and the circadian and sleep-related outcomes that interest the biohacker community.

Blood-Brain Barrier Penetration

Khavinson’s group published studies using radioactively labelled EDR peptide showing tissue distribution consistent with central nervous system penetration after systemic administration in rodents. The blood-brain barrier permeability of short peptides (three amino acids) is more plausible than for larger molecules, but independent verification using rigorous pharmacokinetic methods has not been published.

The bottom line: Pinealon is proposed to work by crossing cell and nuclear membranes and interacting directly with DNA promoter regions of neuroprotective and antioxidant genes – a mechanism that, if confirmed, would be unusual among therapeutic peptides.

The published evidence for pinealon consists entirely of in vitro cell studies, rodent models and one in vivo Alzheimer’s disease mouse model. No human clinical trials have been completed. Essentially all published research originates from Khavinson’s group and affiliated institutions at the Saint Petersburg Institute of Bioregulation and Gerontology.

Neuroprotection and Oxidative Stress

A 2011 in vitro study in Rejuvenation Research by Khavinson, Ribakova, Kulebiakin and colleagues reported dose-dependent suppression of reactive oxygen species (ROS) and increased cell viability in neuronal cultures treated with pinealon. A 2014 paper by Mendzheritskii, Karantysh, Ryzhak and Dem’ianenko examined pinealon combined with Cortexin in aged rats under acute hypoxic conditions, reporting reduced serum cytokine levels and decreased brain caspase-3 activity – a marker of apoptotic cell death.

Prenatal Neuroprotection

A 2012 preclinical study by Arutjunyan, Kozina, Stvolinskiy and colleagues, published in International Journal of Clinical and Experimental Medicine, reported that maternal pinealon administration protected rat offspring against prenatal hyperhomocysteinemia-induced neurodevelopmental damage. The treated offspring showed improved spatial learning and memory in behavioural tests, with significant reductions in both ROS accumulation and necrotic cell counts in brain tissue.

Alzheimer’s Disease Mouse Model

A 2021 study by Khavinson, Ilina, Kraskovskaya, Linkova and colleagues in Pharmaceuticals used the 5xFAD transgenic Alzheimer’s mouse model to test pinealon alongside the related tripeptide KED. Daily intraperitoneal administration of EDR peptide from 2 to 4 months of age prevented dendritic spine loss in 5xFAD-M mice. The molecular modelling component identified DNA binding sites in the promoter regions of genes relevant to Alzheimer’s pathogenesis, including CASP3 and APOE.

Cellular Aging and Skin Cells

A 2012 study by Voicekhovskaya, Chalisova, Kontsevaya and Ryzhak in Bulletin of Experimental Biology and Medicine examined pinealon’s effects on skin cell cultures from young and old rats, reporting increased cell viability through suppression of free radical levels and activation of proliferative processes. A 2024 study by Kraskovskaya, Linkova, Sakhenberg and colleagues in International Journal of Molecular Sciences reported that short peptides including EDR protect fibroblast-derived induced neurons from age-related changes.

The Huberman REM Sleep Report

In an October 2024 Huberman Lab podcast episode featuring Dr. Craig Koniver, neuroscientist Andrew Huberman reported that pinealon use over four to six months doubled his REM sleep – from approximately 1-1.5 hours to nearly 3 hours per night, tracked with a sleep-monitoring device. Huberman described pinealon as the only compound he had found that improved REM sleep quantity, and noted that the effect persisted even on nights he did not take the peptide. He and Koniver speculated this could indicate pinealocyte functional regeneration, though no published research supports this specific claim for pinealon.

Study	Model	Key Finding	Evidence Tier
Khavinson et al. 2011, Rejuvenation Research	In vitro neuronal cultures	Dose-dependent ROS suppression, increased cell viability	Preclinical (cell)
Arutjunyan et al. 2012, IJCEM	Prenatal rat (hyperhomocysteinemia)	Offspring neuroprotection, improved spatial learning	Preclinical (animal)
Mendzheritskii et al. 2014, Adv Gerontol	Aged rats, acute hypoxia	Reduced cytokines, decreased brain caspase-3	Preclinical (animal)
Khavinson et al. 2021, Pharmaceuticals	5xFAD-M Alzheimer’s mice	Prevented dendritic spine loss	Preclinical (animal)
Kraskovskaya et al. 2024, IJMS	Fibroblast-derived neurons	Protected induced neurons from age-related changes	Preclinical (cell)
Huberman / Koniver, Oct 2024 podcast	Single individual (self-report)	Doubled REM sleep over 4-6 months	Anecdotal (n=1)

The bottom line: Pinealon’s preclinical evidence shows neuroprotective effects across multiple in vitro and rodent models, with the 5xFAD Alzheimer’s study representing the strongest disease-relevant data, but no human clinical trial has been completed and the evidence base originates almost entirely from one research group.

Cortexin, the polypeptide extract from which pinealon was originally isolated, is a registered pharmaceutical product in Russia – not a research reagent. It is manufactured by GEROPHARM and approved for clinical use in acute ischaemic stroke, perinatal brain injuries in children and cognitive disorders, with decades of prescribing history across Russia, Eastern Europe and parts of Asia.

Cortexin is a lyophilised extract of animal cerebral cortex containing multiple polypeptide fractions (molecular weight 1,000-10,000 Da), L-amino acids, vitamins and trace elements. Its mechanism is described as multimodal: activation of neuronal peptides and neurotrophic cerebral factors, optimisation of excitatory and inhibitory amino acid balance, modulation of dopamine, serotonin and GABAergic activity. A 2015 review by Gulyaeva in Neuroscience and Behavioral Physiology characterised its molecular targets.

This context matters because pinealon is essentially one purified active fraction of a drug product with real clinical exposure. The Khavinson group’s hypothesis is that short peptide bioregulators like EDR are the biologically active components responsible for Cortexin’s therapeutic effects. Whether this “active fraction” hypothesis is correct remains unproven, but it means pinealon’s parent compound has a pharmaceutical track record that most peptides in the longevity space lack entirely. No Western regulatory body has approved Cortexin, and the Russian clinical evidence has not been subjected to ICH-standard review, but the safety database from decades of clinical use is a relevant data point.

The bottom line: Pinealon was isolated from Cortexin, a registered pharmaceutical in Russia with decades of clinical prescribing history for stroke and neurological conditions – a pharmaceutical lineage that distinguishes it from peptides developed purely as research compounds.

Pinealon shares a limitation with epitalon and other Khavinson bioregulators: the published research base originates overwhelmingly from the same institutional network. The Saint Petersburg Institute of Bioregulation and Gerontology and its affiliated researchers have produced nearly all primary experimental data on pinealon. The 2020 and 2022 review papers by Khavinson, Linkova, Ilina, Kozhevnikova and colleagues in Molecules and International Journal of Molecular Sciences frame the DNA-interaction mechanism as a hypothesis with biophysical support at the molecular level, and the papers are transparent about the speculative status of the gene-expression model.

Independent replication by researchers outside this network has not been published. This does not invalidate the findings, but it means the evidence should be weighted accordingly. In the ischemia models, most studies used pretreatment designs – administering pinealon before the ischemic insult rather than after. Pre-injury neuroprotection is pharmacologically easier to demonstrate than post-injury treatment, which limits translational relevance.

The bottom line: The absence of independent replication is the single largest gap in pinealon’s evidence base and should inform any assessment of its therapeutic potential.

Pinealon is not approved as a drug in any major regulatory jurisdiction. Unlike several other peptides in the longevity cluster, it was not placed on the FDA’s Category 2 restricted list during the 2023-2024 enforcement wave and is not among the 12 peptides removed from Category 2 on April 15, 2026. It was never nominated for the 503A Bulks List evaluation process. For how individual countries regulate peptides more broadly, see our guides for the US, the UK and Australia.

Jurisdiction	Status	Notes
United States (FDA)	Not approved, not restricted	Never placed on Category 2 list. Available via physician prescription and 503A/503B compounding pharmacies. Not scheduled for PCAC review.
United Kingdom (MHRA)	Not licensed	No marketing authorisation. Sale for human consumption is unlawful without a licence.
Australia (TGA)	Not approved	Not scheduled. No TGA registration or listing.
WADA	Not listed	Not individually named on the 2024 Prohibited List.

The wider regulatory landscape for peptides is explained in our FDA Category 1 vs Category 2 explainer and the RFK reclassification tracker.

The bottom line: Pinealon occupies an unusual regulatory position – it was never restricted under the 2023-2024 Category 2 wave and remains available through physician-supervised compounding, but it has no approved indication in any country.

No significant toxic, allergic, mutagenic or carcinogenic effects have been reported across the published literature on pinealon. The EDR peptide has been characterised in the Khavinson literature as having high biological activity and tissue specificity, with an absence of species-specificity and immunogenicity – properties attributed to the endogenous nature of these signalling molecules. In cellular studies, the EDR peptide demonstrated dose-dependent effects without evidence of cytotoxicity across the concentration ranges tested. In animal models involving both young and aged rats, pinealon administration did not produce observable adverse effects.

However, the safety profile must be understood in context: no controlled human trials have been conducted, no formal toxicology studies meeting regulatory standards have been published, and long-term safety data in humans does not exist. The absence of reported adverse effects in Russian preclinical literature is not equivalent to a confirmed human safety profile. For guidance on evaluating peptide source quality, see our guide on how to read a certificate of analysis.

The bottom line: No adverse effects have been reported in published preclinical studies, but the absence of human safety trials means pinealon’s safety profile in humans is uncharacterised.

Pinealon sits within the Khavinson bioregulator family and the broader longevity peptide landscape. Epitalon (AEDG) is the most frequently compared compound – both originated from Khavinson’s pineal research, but epitalon targets telomerase activation and melatonin synthesis while pinealon targets neuronal gene expression and antioxidant defence. The full head-to-head comparison is covered in our epitalon vs pinealon guide.

SS-31 (elamipretide) targets mitochondrial function through an entirely different mechanism – cardiolipin stabilisation on the inner mitochondrial membrane. FOXO4-DRI takes a senolytic approach, selectively eliminating senescent cells rather than protecting healthy ones. The Khavinson bioregulators overview covers the full range of tissue-specific bioregulators beyond pinealon and epitalon.

What is pinealon?

Pinealon is a synthetic tripeptide composed of glutamic acid, aspartic acid and arginine (Glu-Asp-Arg, also called EDR). It was developed at the Saint Petersburg Institute of Bioregulation and Gerontology as part of the Khavinson bioregulator peptide research programme. It is classified as a neuroprotective peptide bioregulator proposed to interact directly with DNA promoter regions rather than cell-surface receptors.

Does pinealon actually improve sleep?

No controlled human study has measured pinealon’s effects on sleep architecture. Neuroscientist Andrew Huberman publicly reported that pinealon doubled his REM sleep over four to six months, but this is a single individual’s observation tracked with a consumer sleep device, not clinical evidence. A plausible mechanistic link exists through TPH1 upregulation (which supports serotonin and downstream melatonin production), but this pathway has only been demonstrated in cell culture.

Is pinealon FDA-approved?

No. Pinealon has not been approved by the FDA for any indication. It was not placed on the Category 2 restricted list and is available through physician prescription and licensed compounding pharmacies in the United States. It is not scheduled for PCAC review.

What is the difference between pinealon and epitalon?

Both are Khavinson bioregulator peptides from the same research programme, but they differ in sequence and primary mechanism. Epitalon is a tetrapeptide (AEDG) targeting telomerase activation and melatonin synthesis. Pinealon is a tripeptide (EDR) targeting neuronal gene expression, antioxidant defence and neuroprotection. Despite the name, pinealon was isolated from brain cortex extract, not pineal tissue.

Does pinealon’s parent compound Cortexin have a safety record?

Cortexin, the polypeptide brain extract from which pinealon was isolated, is a registered pharmaceutical in Russia with decades of clinical prescribing history. Its approved prescribing information lists individual hypersensitivity as the only reported adverse reaction. However, pinealon is a single purified fraction of Cortexin, not the whole extract, and no formal toxicology studies on pinealon alone meeting Western regulatory standards have been published. The Cortexin safety record provides context but is not a substitute for dedicated human safety trials on pinealon.

Does pinealon have any performance-enhancing classification?

Pinealon is not individually named on WADA’s 2024 Prohibited List and has no known ergogenic mechanism. Its proposed action is neuroprotective gene-expression modulation, which does not fall within any current WADA prohibited substance category. By contrast, MOTS-c in the same longevity cluster is explicitly prohibited under S4.4.1 as an AMPK activator. Athletes should still verify current status directly with their sport’s anti-doping authority.

Why is all the pinealon research from one group?

Pinealon was developed and primarily investigated by Khavinson’s group at the Saint Petersburg Institute of Bioregulation and Gerontology. The concentration of evidence from a single research lineage is common for bioregulator peptides and reflects both the specificity of the research programme and the limited Western academic interest in these compounds. Independent replication remains the critical gap in pinealon’s evidence base.